Drugs / Purified Exosome Product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06429033 | Apr → Dec 2025 | — | Clinical Testing of Beverly Hills | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Purified Exosome Product | “PEP (Purified Exosome Product)” NCT06429033 ↗ |
| Known as | PEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06429033 ↗ |
| Modality | Other / unclassified | “PEP (Purified Exosome Product)” NCT06429033 ↗ |
| Route | Subcutaneous | “safety of subcutaneous PEP Drug Product” NCT06429033 ↗ |